At OMB: Hear No Evil, See No Evil?

In an upbeat and collegial Science magazine editorial in June (F.D. Raines, Science, 280:1671, 1998), the outgoing director of the federal Office of Management and Budget (OMB), Franklin D. Raines, addressed how the scientific community might better help to maintain the Clinton administration's commitment to R&D. Raines alluded to the "excitement and wonder of science" and called for better measures of the success of research, greater priority-setting for research fields, and ways to stren

Written byHenry Miller
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

In an upbeat and collegial Science magazine editorial in June (F.D. Raines, Science, 280:1671, 1998), the outgoing director of the federal Office of Management and Budget (OMB), Franklin D. Raines, addressed how the scientific community might better help to maintain the Clinton administration's commitment to R&D. Raines alluded to the "excitement and wonder of science" and called for better measures of the success of research, greater priority-setting for research fields, and ways to strengthen the government-university partnership.

But there is an almost surreal element of "hear no evil, see no evil" in Raines's article. He seems to have forgotten that federal regulation of science, as well as its funding, was under his purview at OMB, which has the responsibility for final sign-off on all federal regulations. During Raines's tenure, regulation of research, especially academic research, has been federal agencies' b[E WITH CARAT]te noire. Treatment of the new biotechnology by the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies